1046 – Safety and Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Children 20 to 40 kg
Background Long-acting cabotegravir (CAB-LA) plus long-acting rilpivirine (RPV-LA) are approved for maintenance of viral suppression in adults and adolescents >35kg with HIV-1 infection. IMPAACT 2036 (CRAYON) is a Phase I/II, multi-center, open-label, non-comparative study to evaluate safety, tolerability, acceptability and pharmacokinetics (PK) of oral (PO) and intramuscular (IM) CAB-LA+RPV-LA in children 2-<12 years, living with HIV-1.…